BOSTON–(BUSINESS WIRE)–Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a computational drug discovery company developing breakthrough small molecule medicines through advanced structure-based design and AI-enabled chemistry, today announced that it will present new preclinical data from its highly selective salt-inducible kinase 2 (SIK2) inhibitor program in rheumatoid arthritis (RA) at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, taking plac
